Your browser doesn't support javascript.
loading
Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice.
Zhou, Rongrong; Llorente, Cristina; Cao, Jinling; Zaramela, Livia S; Zeng, Suling; Gao, Bei; Li, Shang-Zhen; Welch, Ryan D; Huang, Feng-Qing; Qi, Lian-Wen; Pan, Chuyue; Huang, Yan; Zhou, Pengchen; Beussen, Iris; Zhang, Ying; Bryam, Gregory; Fiehn, Oliver; Wang, Lirui; Liu, E-Hu; Yu, Ruth T; Downes, Michael; Evans, Ronald M; Goglin, Karrie; Fouts, Derrick E; Brenner, David A; Bode, Lars; Fan, Xuegong; Zengler, Karsten; Schnabl, Bernd.
Afiliación
  • Zhou R; Department of Infectious Diseases, Xiangya Hospital, Central South University and Key Laboratory of Viral Hepatitis, Hunan, Changsha, China; Department of Medicine, University of California San Diego, La Jolla, California.
  • Llorente C; Department of Medicine, University of California San Diego, La Jolla, California.
  • Cao J; Department of Medicine, University of California San Diego, La Jolla, California; College of Food Science and Engineering, Shanxi Agricultural University, Shanxi, Taigu, China.
  • Zaramela LS; Department of Pediatrics, University of California San Diego, La Jolla, California.
  • Zeng S; Department of Medicine, University of California San Diego, La Jolla, California; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Gao B; Department of Medicine, University of California San Diego, La Jolla, California.
  • Li SZ; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Welch RD; Gene Expression Laboratory, Salk Institute for Biological Studies, San Diego, California.
  • Huang FQ; The Clinical Metabolomics Center, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Qi LW; The Clinical Metabolomics Center, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Pan C; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Huang Y; Department of Infectious Diseases, Xiangya Hospital, Central South University and Key Laboratory of Viral Hepatitis, Hunan, Changsha, China.
  • Zhou P; Department of Infectious Diseases, Xiangya Hospital, Central South University and Key Laboratory of Viral Hepatitis, Hunan, Changsha, China.
  • Beussen I; National Institutes of Health West Coast Metabolomics Center, University of California, Davis, California.
  • Zhang Y; National Institutes of Health West Coast Metabolomics Center, University of California, Davis, California; Department of Chemistry, University of California, Davis, California.
  • Bryam G; National Institutes of Health West Coast Metabolomics Center, University of California, Davis, California.
  • Fiehn O; National Institutes of Health West Coast Metabolomics Center, University of California, Davis, California.
  • Wang L; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Liu EH; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Yu RT; Gene Expression Laboratory, Salk Institute for Biological Studies, San Diego, California.
  • Downes M; Gene Expression Laboratory, Salk Institute for Biological Studies, San Diego, California.
  • Evans RM; Gene Expression Laboratory, Salk Institute for Biological Studies, San Diego, California.
  • Goglin K; J. Craig Venter Institute, La Jolla, California.
  • Fouts DE; J. Craig Venter Institute, Rockville, Maryland.
  • Brenner DA; Department of Medicine, University of California San Diego, La Jolla, California.
  • Bode L; Department of Pediatrics and Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence, University of California San Diego, La Jolla, California.
  • Fan X; Department of Infectious Diseases, Xiangya Hospital, Central South University and Key Laboratory of Viral Hepatitis, Hunan, Changsha, China.
  • Zengler K; Department of Pediatrics, University of California San Diego, La Jolla, California; Department of Bioengineering, University of California San Diego, La Jolla, California.
  • Schnabl B; Department of Medicine, University of California San Diego, La Jolla, California; Department of Medicine, VA San Diego Healthcare System, San Diego, California. Electronic address: beschnabl@ucsd.edu.
Cell Mol Gastroenterol Hepatol ; 12(1): 293-320, 2021.
Article en En | MEDLINE | ID: mdl-33631374
ABSTRACT
BACKGROUND &

AIMS:

Fucosyltransferase 2 (Fut2)-mediated intestinal α1- 2-fucosylation is important for host-microbe interactions and has been associated with several diseases, but its role in obesity and hepatic steatohepatitis is not known. The aim of this study was to investigate the role of Fut2 in a Western-style diet-induced mouse model of obesity and steatohepatitis.

METHODS:

Wild-type (WT) and Fut2-deficient littermate mice were used and features of the metabolic syndrome and steatohepatitis were assessed after 20 weeks of Western diet feeding.

RESULTS:

Intestinal α1-2-fucosylation was suppressed in WT mice after Western diet feeding, and supplementation of α1-2-fucosylated glycans exacerbated obesity and steatohepatitis in these mice. Fut2-deficient mice were protected from Western diet-induced features of obesity and steatohepatitis despite an increased caloric intake. These mice have increased energy expenditure and thermogenesis, as evidenced by a higher core body temperature. Protection from obesity and steatohepatitis associated with Fut2 deficiency is transmissible to WT mice via microbiota exchange; phenotypic differences between Western diet-fed WT and Fut2-deficient mice were reduced with antibiotic treatment. Fut2 deficiency attenuated diet-induced bile acid accumulation by altered relative abundance of bacterial enzyme 7-α-hydroxysteroid dehydrogenases metabolizing bile acids and by increased fecal excretion of secondary bile acids. This also was associated with increased intestinal farnesoid X receptor/fibroblast growth factor 15 signaling, which inhibits hepatic synthesis of bile acids. Dietary supplementation of α1-2-fucosylated glycans abrogates the protective effects of Fut2 deficiency.

CONCLUSIONS:

α1-2-fucosylation is an important host-derived regulator of intestinal microbiota and plays an important role for the pathogenesis of obesity and steatohepatitis in mice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hígado Graso / Fucosiltransferasas / Intestinos / Obesidad Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cell Mol Gastroenterol Hepatol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hígado Graso / Fucosiltransferasas / Intestinos / Obesidad Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cell Mol Gastroenterol Hepatol Año: 2021 Tipo del documento: Article